These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30527460)

  • 1. Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Paredes AZ; Abdel-Misih S; Schmidt C; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Feb; 234():103-109. PubMed ID: 30527460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
    Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Outcomes After Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Gani F; Conca-Cheng AM; Nettles B; Ahuja N; Johnston FM
    J Surg Res; 2019 Feb; 234():240-248. PubMed ID: 30527480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Li KY; Mokdad AA; Minter RM; Mansour JC; Choti MA; Augustine MM; Polanco PM
    J Surg Res; 2017 Jun; 214():209-215. PubMed ID: 28624046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
    Lu PW; Fields AC; Shabat G; Bleday R; Goldberg JE; Irani J; Stopfkuchen-Evans M; Melnitchouk N
    J Surg Res; 2020 Mar; 247():59-65. PubMed ID: 31767280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Kelly KJ; Cajas L; Baumgartner JM; Lowy AM
    Ann Surg Oncol; 2018 Jan; 25(1):91-97. PubMed ID: 29090402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to Thrive Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Causes and Consequences.
    Rieser CJ; Alvikas J; Phelos H; Hall LB; Zureikat AH; Lee A; Ongchin M; Holtzman MP; Pingpank JF; Bartlett DL; Choudry MHA
    Ann Surg Oncol; 2022 Apr; 29(4):2630-2639. PubMed ID: 34988834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study.
    Lee TC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Ahmed A; Fournier K; Lee AJ; Dineen S; Powers B; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Zaidi MY; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Abbott DE; Pokrzywa C; Blakely AM; Lee B; Johnston FM; Greer J; Patel SH
    J Gastrointest Surg; 2020 Jan; 24(1):165-176. PubMed ID: 31745888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program.
    Jafari MD; Halabi WJ; Stamos MJ; Nguyen VQ; Carmichael JC; Mills SD; Pigazzi A
    JAMA Surg; 2014 Feb; 149(2):170-5. PubMed ID: 24352601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC.
    Burguete D; Mokdad AA; Augustine MM; Minter R; Mansour JC; Choti MA; Polanco PM
    J Surg Res; 2019 Jan; 233():360-367. PubMed ID: 30502272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program.
    Hinkle NM; MacDonald J; Sharpe JP; Dickson P; Deneve J; Munene G
    Am J Surg; 2016 Sep; 212(3):413-8. PubMed ID: 27086201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.